HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026

HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026 Three abstracts accepted across HCB101 and HCB301, including the gastric cancer Best Poster Presentation Award and Poster Discussion TAIPEI, SHANGHAI, and SAN FRANCISCO — August 19, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea. The presentations include two posters on HCB101 clinical development in gastric cancer (GC) and head and neck squamous cell carcinoma (HNSCC), as well as an oral presentation of first-in-human clinical data for HCB301, HanchorBio’s tri-specific SIRPα–PD-L1–TGFβ fusion protein. The HCB101 gastric cancer abstract has also been selected for the KSMO 2026 Best Poster Presentation Award and a Poster Discussion presentation. According to KSMO, only outstanding abstracts were selected for the Poster Discussion sessions. “We are pleased to have three clinical presentations selected for KSMO 2026 and FACO across two programs from our FBDB™ platform,” said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. “HCB101 and HCB301 represent our innovative approaches to overcoming immune resistance, from activating macrophage-mediated antitumor immunity to integrating and synergizing multiple immune pathways within a single therapeutic molecule. We look forward to sharing our progress with the oncology community in Seoul.” Alvin Luk, Ph.D., M.B.A., C.C.R.A., President and Chief Medical Officer (Group) & CEO (USA) of HanchorBio, will deliver the HCB301 oral presentation. HanchorBio Presentations at KSMO 2026 / FACO HCB101 — Gastric Cancer Preliminary Antitumor Activity of HCB101 (SIRPα-Fc Fusion Protein)-Based Combination Therapy in Advanced Gastric Cancer Presentation: Best Poster Presentation Award / Poster Discussion (In-Person Presentation) Date:September 3, 2026 Poster Discussion Session:14:50–15:20 KST Presentation Format:4-minute presentation + 2-minute real-time Q&A Presentation Code/Location: PD01/Carnation Room (5 Floor) HCB101 — Head and Neck Squamous Cell Carcinoma HCB101 in HNSCC: Early Clinical Evidence Supporting PD-1- and EGFR-Directed Combination Strategies Presentation:Poster Date:September 3, 2026

The release as fetched from its publisher. hanchorbio.com ↗